MilliporeSigma
  • Home
  • Search Results
  • Cardiovascular complications following chronic treatment with cocaine and testosterone in adolescent rats.

Cardiovascular complications following chronic treatment with cocaine and testosterone in adolescent rats.

PloS one (2014-08-15)
Sheila A Engi, Fábio C Cruz, Rodrigo M Leão, Luís C Spolidorio, Cleopatra S Planeta, Carlos C Crestani
ABSTRACT

Concomitant use of anabolic androgenic steroids and cocaine has increased in the last years. However, the effects of chronic exposure to these substances during adolescence on cardiovascular function are unknown. Here, we investigated the effects of treatment for 10 consecutive days with testosterone and cocaine alone or in combination on basal cardiovascular parameters, baroreflex activity, hemodynamic responses to vasoactive agents, and cardiac morphology in adolescent rats. Administration of testosterone alone increased arterial pressure, reduced heart rate (HR), and exacerbated the tachycardiac baroreflex response. Cocaine-treated animals showed resting bradycardia without changes in arterial pressure and baroreflex activity. Combined treatment with testosterone and cocaine did not affect baseline arterial pressure and HR, but reduced baroreflex-mediated tachycardia. None of the treatments affected arterial pressure response to either vasoconstrictor or vasodilator agents. Also, heart to body ratio and left and right ventricular wall thickness were not modified by drug treatments. However, histological analysis of left ventricular sections of animals subjected to treatment with testosterone and cocaine alone and combined showed a greater spacing between cardiac muscle fibers, dilated blood vessels, and fibrosis. These data show important cardiovascular changes following treatment with testosterone in adolescent rats. However, the results suggest that exposure to cocaine alone or combined with testosterone during adolescence minimally affect cardiovascular function.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
(R)-(−)-Phenylephrine hydrochloride, powder
Sigma-Aldrich
(R)-(−)-Phenylephrine hydrochloride, analytical standard
Sigma-Aldrich
Sodium nitroprusside dihydrate, puriss. p.a., ACS reagent, reag. Ph. Eur., ≥99%
Phenylephrine hydrochloride for peak identification, European Pharmacopoeia (EP) Reference Standard
Supelco
Cocaine hydrochloride solution, 1.0 mg/mL in methanol, analytical standard, for drug analysis
Sigma-Aldrich
Cocaine hydrochloride
Supelco
Flunixin Meglumine, Pharmaceutical Secondary Standard; Certified Reference Material
USP
Phenylephrine hydrochloride, United States Pharmacopeia (USP) Reference Standard
Flunixin meglumine, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Flunixin meglumine, ≥98% (HPLC)
Phenylephrine hydrochloride, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Sodium nitroferricyanide(III) dihydrate, ACS reagent, ≥99%
Supelco
Phenylephrine Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material